Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

In patients ineligible for transplantation, the combination of lenalidomide and dexamethasone with lenalidomide maintenance until disease progression achieved significantly improved progression-free survival, as compared with melphalan, prednisone, and thalidomide therapy. For patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation, the standard therapy is melphalan and prednisone (MP) combined with either thalidomide (MPT) or bortezomib (VMP). 1 – 10 Lenalidomide (Revlimid, Celgene) is an immunomodulatory drug that, in combination with dexamethasone, is a standard treatment option for patients with multiple myeloma who have received at least one prior therapy as approved by the Food and Drug Administration and the European Medicines Agency. 7 – 13 In a randomized trial that included both younger and older patients with newly diagnosed multiple myeloma, lenalidomide plus low-dose dexamethasone was associated with fewer adverse . . .